Internal FDA memos reported by the Washington Post last week show senior scientists at the FDA disagreed sharply with the agency's decision last month to bar the Plan B morning-after pill from over-the-counter sales. The scientists asserted that FDA officials applied a higher standard for determining Plan B's OTC status than has been applied to other drugs. Dr. John Jenkins, director of FDA's Office of New Drugs, wrote in an internal memo reported in the Wall Street Journal that Plan B is "fully consistent with the agency's usual standards for meeting the criteria" for OTC status.